Nuzenio

Unchanged Price Target

Unchanged Price Target news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 24 latest news signals 2 publisher sources 100/100 entity strength

Latest news

Analyst Reiterates Buy on Monday.com as AI Momentum Builds and Profitability Improves; Price Target Unchanged at $125 - TipRanksTipRanks · Mon, 10 Aug 2026 21:19:04 GMTJazz Pharmaceuticals: Buy Rating Reiterated as Actio Bioscience Acquisition and ABS-1230 Growth Potential Support Unchanged $307 Price Target - TipRanksTipRanks · Mon, 10 Aug 2026 17:29:04 GMTASML’s Moat Intact: Scemama Reiterates Buy Rating with Unchanged €2,452 Price Target on Lithography Leadership and Throughput Roadmap - TipRanksTipRanks · Mon, 10 Aug 2026 16:49:23 GMTCullinan Oncology: Buy Rating Reaffirmed with Unchanged $30 Price Target on Robust Pipeline and Strong Cash Position - TipRanksTipRanks · Mon, 10 Aug 2026 11:06:35 GMTCVS Health: Buy Rating Reaffirmed as Strong Earnings Outlook and Segment Outperformance Support Unchanged $110 Price Target - TipRanksTipRanks · Mon, 10 Aug 2026 04:59:47 GMTAnalyst Maintains Buy on Janux Therapeutics, Keeps $60 Price Target Unchanged on Strong Balance Sheet and Clinical Differentiation - TipRanksTipRanks · Fri, 07 Aug 2026 21:07:19 GMTINOD Maintained by BWS Financial -- Price Target Unchanged at $1 - GuruFocusGuruFocus · Fri, 07 Aug 2026 18:00:00 GMTAnalyst Reiterates Hold on DraftKings as Outlook and $27 Price Target Remain Unchanged Amid Profitability Concerns - TipRanksTipRanks · Fri, 07 Aug 2026 12:19:25 GMT

Timeline

Mon, 10 Aug 2026 21:19:04 GMTAnalyst Reiterates Buy on Monday.com as AI Momentum Builds and Profitability Improves; Price Target Unchanged at $125 - TipRanks
Mon, 10 Aug 2026 17:29:04 GMTJazz Pharmaceuticals: Buy Rating Reiterated as Actio Bioscience Acquisition and ABS-1230 Growth Potential Support Unchanged $307 Price Target - TipRanks
Mon, 10 Aug 2026 16:49:23 GMTASML’s Moat Intact: Scemama Reiterates Buy Rating with Unchanged €2,452 Price Target on Lithography Leadership and Throughput Roadmap - TipRanks
Mon, 10 Aug 2026 11:06:35 GMTCullinan Oncology: Buy Rating Reaffirmed with Unchanged $30 Price Target on Robust Pipeline and Strong Cash Position - TipRanks
Mon, 10 Aug 2026 04:59:47 GMTCVS Health: Buy Rating Reaffirmed as Strong Earnings Outlook and Segment Outperformance Support Unchanged $110 Price Target - TipRanks
Fri, 07 Aug 2026 21:07:19 GMTAnalyst Maintains Buy on Janux Therapeutics, Keeps $60 Price Target Unchanged on Strong Balance Sheet and Clinical Differentiation - TipRanks

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Unchanged Price Target.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

2 distinct publisher/source names are currently connected to this entity page.